Explain this page
Arphra AIPlain-English read on CVS Health Corporation’s valuation06-08today
- CVS Health (CVS) is a Great Momentum Stock: Should You Buy?2d
- CVS Health's Comeback Is Just Getting Started -- and Its Valuation Still Looks Shockingly Cheap6d
- 1 Top Wall Street Analyst Thinks CVS Health Could Jump Another 13%. Should You Load Up on the Stock?6d
- 5 Low Price-to-Book Stocks That Are Worth Buying in June9d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$415.68
+322.78% vs spot
Recommendation
Strong Buy
17 of 19 methods
Method spread
7bull10bear
±5% threshold
Analyst PT consensus: $103.64 (+5.41%)
Candlestick · 1Y
Open in chart workstation →CVS
98.32+47.16%H 102.77L 58.50MA50 88.74MA200 80.22Avg vol 8.0M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.85% | -2.52% | +5.36% | +37.55% | +26.51% | +23.89% | +47.16% | +42.97% | +17.02% | +5.48% | +14576.38% |
Insider · 30d
History →Bought
$2.1M
2 txns
Sold
$254.73M
8 txns
Net flow
−$252.63M
Aftermarket
LiveLast trade
$98.40
Bid
$97.50
10 sh
Ask
$99.52
11 sh
Spread
$2.020
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $105.69B | $2.94B | $2.30 |
| Q3 Sep 2025 | $102.87B | -$3.98B | $-3.13 |
| Q2 Jun 2025 | $98.92B | $1.02B | $0.80 |
| Q1 Mar 2025 | $94.59B | $1.78B | $1.41 |
| Q4 Dec 2024 | $97.71B | $1.64B | $1.30 |
| Q3 Sep 2024 | $95.43B | $87M | $0.07 |
Sector & industry today
LiveSectors
- Communication Services+1.85%
- Utilities+1.35%
- Consumer Cyclical+0.30%
- Energy-0.45%
- Industrials-0.48%
- Basic Materials-0.66%
- Financial Services-0.67%
- Technology-0.95%
- Healthcare-1.51%
- Consumer Defensive-1.52%
- Real Estate-2.19%
Top industries (issuer's industry highlighted)
No industry data returned.
Analyst view
DB · price_targets + analyst_gradesConsensus target
$103.64
+5.41% upside
Low
$90.00
Median
$106.00
High
$115.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- CVS Health (CVS) is a Great Momentum Stock: Should You Buy?zacks.com·Jun 19, 2026
- CVS Health's Comeback Is Just Getting Started -- and Its Valuation Still Looks Shockingly Cheapfool.com·Jun 16, 2026
- 1 Top Wall Street Analyst Thinks CVS Health Could Jump Another 13%. Should You Load Up on the Stock?fool.com·Jun 15, 2026
- 5 Low Price-to-Book Stocks That Are Worth Buying in Junezacks.com·Jun 12, 2026
- CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?zacks.com·Jun 12, 2026
- CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on Itzacks.com·Jun 12, 2026
- Healthy Returns: CVS Health executives on reducing health care's biggest pain pointscnbc.com·Jun 11, 2026
- Trump's Economy Hired Nearly 1 Million Healthcare Workers While Every Other Sector Lost Jobs. Here's Where to Put Your Money247wallst.com·Jun 10, 2026
Recent analyst activity
DB- Jun 11, 2026GradeOverweight → OverweightCVS Health (CVS) Reiterated at Overweight by Cantor Fitzgerald on Medicaid IncumbencyCantor Fitzgerald
- Jun 08, 2026PT$115.00CVS Health price target raised to $115 from $110 at MizuhoMizuho Securities
- Jun 04, 2026GradeOverweight → OverweightCVS Health price target raised to $111 from $106 at Morgan StanleyMorgan Stanley
- Jun 04, 2026PT$111.00CVS Health price target raised to $111 from $106 at Morgan StanleyMorgan Stanley
- Jun 01, 2026PT$108.00CVS Health price target raised to $108 from $102 at TruistTruist Financial
- Jun 01, 2026GradeOverweight → OverweightPiper Sandler Reiterates Overweight Rating on CVS Health (CVS)Piper Sandler
- Jun 01, 2026PT$113.00Piper Sandler Reiterates Overweight Rating on CVS Health (CVS)Piper Sandler
Financial scores
DBJun 19, 2026Altman Z
2.43
Grey
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
7/9
Strong
≥ 7 strong · 4–6 average · < 4 weak
Peers
Total assets
$261.06B
Total debt
$93.59B
Cash & equiv
$8.51B
Operating CF
$10.64B
Free cash flow
$7.81B
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Finucane Anne A. director | Sell | 7,500 | $532.65K | Aug 20, 2025 |
SANSONE GUY P director | Buy | 1,570 | $100.01K | Jun 05, 2025 |
ROBBINS LARRY director | Sell | 150,000 | $10M | May 06, 2025 |
ROBBINS LARRY director | Sell | 1M | $82.65M | May 05, 2025 |
ROBBINS LARRY director | Sell | 96,999 | $6.6M | May 05, 2025 |
ROBBINS LARRY director | Sell | 222,556 | $15.22M | May 02, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $402.07B | $10.39B | $1.77B | $1.39 | +0.44% |
| FY 2024 | $372.81B | $8.52B | $4.61B | $3.66 | +1.24% |
| FY 2023 | $357.78B | $13.74B | $8.34B | $6.47 | +2.33% |
| FY 2022 | $322.47B | $7.95B | $4.31B | $3.26 | +1.34% |
| FY 2021 | $292.11B | $13.31B | $8B | $5.95 | +2.74% |